DS-1103a clinical trials
DS-1103a is named as an intervention in 2 current clinical trials in our USA, France, Spain, China, Italy, Turkey, Canada, Japan and Taiwan registers. 2 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Daiichi Sankyo. The most-studied condition is Solid Tumor.
Patient leaflets for DS-1103a
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of DS-1103a
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966 · ClinicalTrials.gov ↗ · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
|
Phase 1/2 | Recruiting | Daiichi Sankyo | USA, China, France, Spain, Italy, Turkey |
|
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT05765851 · Advanced Solid Tumor
|
Phase 1 | Recruiting | Daiichi Sankyo | USA, France, Spain, Canada, Japan, Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with DS-1103a
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Daiichi Sankyo | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about DS-1103a trials
How many clinical trials are testing DS-1103a?
2 current trials in our USA, France, Spain, China, Italy, Turkey, Canada, Japan and Taiwan registers name DS-1103a as a drug or biological intervention, as of the registry sync on 29 October 2026. Completed and withdrawn studies are not counted.
Are DS-1103a trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in France, 2 with sites in Spain, 1 with sites in China, 1 with sites in Italy, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Japan and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors DS-1103a clinical trials?
The lead sponsor is Daiichi Sankyo. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how DS-1103a works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DS-1103a works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DS-1103a (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.